ArtiaBio

Licensing Opportunities

ArtiaBio offers licensing opportunities for its highly effective cell line platform technology, for media and feeds, and for its in-house developed biosimilars products. Please contact us for licensing terms.

ArtiaBio Cell Line Development Platform

Research and commercial licensing is available for end-users and for service providers. No royalty is required.

  • CHO K1 platform
  • CHO DG44 platform
  • NS0 platform
  • Sp2/0 platform

Each cell line development platform comes with its own specifically engineered expression vectors and multiple selection markers.


To this point, ArtiaBio technology has been used to create seven cell lines, four manufacturing processes with excellent productivities and product quality. Three of these processes are moving to large scale production soon and they are now available for licensing. The other programs are at the cell line development stage and soon will be moving to process development stage.


ArtiaBio Media and Feeds


We have chemically defined media and feeds to be used for fed-batch for licensing. We also have very productive media for continuous perfusion. These media and feed can sustain 30-40 million cells/ml in fed-batch and 50-100 million cells/ml in perfusion (1-2 Volume per day). Licensing available for end-users and for service providers. No royalty is required.

  • CHO fed-batch media and feed platform
  • CHO perfusion media
  • NS0 fed-batch media and feed platform
  • NS0 perfusion media
  • Sp2/0 fed-batch media and feed platform
  • Sp2/0 perfusion media